Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma

scientific article

Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/028418602317314127
P698PubMed publication ID11990525
P5875ResearchGate publication ID11378859

P2093author name stringLingyun Li
Amyn M Rojiani
Dietmar W Siemann
P433issue1
P304page(s)91-97
P577publication date2002-01-01
P1433published inActa OncologicaQ326164
P1476titlePreclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma
P478volume41

Reverse relations

cites work (P2860)
Q28543671A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models
Q83390306A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
Q35909593Antineoplastic agents. 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene
Q78594497Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126
Q44412196Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo
Q37458557Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Q33183693Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
Q40328661Evaluations of the renal cell carcinoma model Caki-1 using a silicon based microvascular casting technique
Q42203737Radiotherapy in combination with vascular-targeted therapies
Q26781365Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Q34122191The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
Q37254370Vascular targeted therapies in oncology
Q35805639Vascular-targeting therapies for treatment of malignant disease.

Search more.